Hematological biomarkers for predicting pathologic response to neoadjuvant immunochemotherapy and cycle optimization in locally advanced gastric cancer - Takeaways - MDSpire

Hematological biomarkers for predicting pathologic response to neoadjuvant immunochemotherapy and cycle optimization in locally advanced gastric cancer

  • By

  • Xinglong Lu

  • Xiang Cui

  • Hao Chen

  • Jianling Zhang

  • Shengbing Zhao

  • Baoshun Yang

  • Yang Yang

  • Nan Du

  • Wenxiang Ma

  • Jixi An

  • Yongjiang Yu

  • May 25, 2026

  • 0 min

Share

  • 1

    Pre-treatment neutrophil count and post-treatment albumin levels are independent predictors of major pathologic response in locally advanced gastric cancer.

  • 2

    Post-treatment platelet count is identified as an independent risk factor for incomplete pathologic response in patients undergoing neoadjuvant immunochemotherapy.

  • 3

    Patients with pre-treatment neutrophils below 3.39×10^9/L benefit from receiving four cycles of neoadjuvant therapy, showing higher pathologic response rates.

  • 4

    The study analyzed 246 patients receiving neoadjuvant immunochemotherapy and 147 patients receiving chemotherapy alone to assess hematological indicators.

  • 5

    This research highlights the importance of individual hematological parameters in predicting treatment outcomes for gastric cancer patients.

Original Source(s)

Hematological biomarkers for predicting pathologic response to neoadjuvant immunochemotherapy and cycle optimization in locally advanced gastric cancer

  • by Xinglong Lu, Xiang Cui, Hao Chen, Jianling Zhang, Shengbing Zhao, Baoshun Yang, Yang Yang, Nan Du, Wenxiang Ma, Jixi An, Yongjiang Yu

  • May 25, 2026

Related Content

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms